Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Regeneron Pharmaceuticals
So what: The last few days have been a wild ride for Regeneron shareholders. After soaring Wednesday on positive news related to the company's Zaltrap drug, the stock tanked yesterday on news that has negative implications for a macular degeneration treatment it is developing with Bayer.
Now what: The Food and Drug Administration is expected to decide whether to approve Regeneron's macular degeneration treatment by Aug. 20, giving the drug near-term profit potential. Lucentis, a competing treatment from Roche and Novartis
Interested in more info on Regeneron? Add it to your watchlist by clicking here.